mardi 5 septembre 2017

Onco Actu du 5 septembre 2017

1. Biologie

New insight into how excess belly fat may increase cancer risk [NHS Choices]

Adipose Tissue May Affect Cancer Development in Multiple Ways [AACR]

Cancer’s Invasion Equation [The New Yorker]

4.1 Dép., diag. & prono. - Prostate

A new study claims prostate cancer screenings significantly reduce deaths. Not everyone agrees [STAT]

New Study Offers Support for Prostate Testing [NY Times]

Prostate cancer test saves lives, risks remain [Reuters]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA clears mammography device with option for patient-assisted compression [FDA]

4.12 Biopsies liquides

DNA and protein 'liquid biopsy' for early pancreatic cancer better than either alone [EurekAlert!]

5.12.1 Immunothérapies - partenariats

Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors [EndPoints]

Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors [Takeda]

5.12.2 Immunothérapies - CAR-T

Cellectis shares slump as death puts cell therapy tests on hold [Reuters]

Cellectis Reports Clinical Hold of UCART123 Studies [Cellectis]

In staggering setback, toxic reaction kills Cellectis’ first CAR-T patient, forcing trial halt [EndPoints]

5.12.3 Immunothérapies-combinaisons

FDA warns public over Keytruda myeloma combo risks in wake of Merck trial deaths [FiercePharma]

5.12.5 Immunothérapies - Pharma

Innate Immunotherapeutics likely to shutter, CEO says [STAT]

5.12.8 Immunothérapies - Economie

At $475,000, new cancer drug raises thorny questions about drug pricing — and value [STAT]

A $475,000 cancer drug: Wall Street sees ‘bargain’; patients see ‘completely broken’ system [HealthNewsReview]

5.2 Pharma

Novartis Calls for the Doctor [Bloomberg]

Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. [Novartis]

Novartis names drugs chief as CEO to deliver return to growth [Reuters]

5.2.1 Pharma - Partenariats

Tox prompts Janssen to drop MacroGenics' cancer antibody [FierceBiotech]

5.3.4 Traitements - AMM (FDA, EMA)

Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin) [Pfizer]

FDA Approves Pfizer’s Mylotarg 7 Years After it was Pulled From the Market [RAPS]

FDA approves Mylotarg for treatment of acute myeloid leukemia [FDA]

5.4 Traitements - Economie

NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective [NICE]

5.6 ESMO

ESMO 2017 Press Release: Study Highlights Overuse of Tumour Marker Tests in Primary and Secondary Care [ESMO]

5.6.14 ESMO - Ovaire

ESMO 2017 Press Release: ICON8 Trial Reaffirms Standard Dosing in Ovarian Cancer Chemo [ESMO]

5.6.2 ESMO - Divers

ESMO 2017 Press Release: MIRO Trial: 3-year Outcomes Favour Laparoscopic Surgery for Oesophageal Cancer [ESMO]

5.6.6 ESMO - Sein

ESMO 2017 Press Release: Study in Early Stage Breast Cancer Shows That Even Small Tumours Can Be Aggressive [ESMO]

6. Lutte contre les cancers

Last Month in Oncology with Dr Bishal Gyawali: August 2017 [ecancernews]

6.1 Observation

More older men get prostate radiation when doctors own the equipment [Reuters]